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Abstract
Brain accumulation and aggregation of amyloid-β (Aβ) peptides is a critical step in the pathogenesis of Alzheimer’s disease 
(AD). Full-length Aβ peptides (mainly Aβ1–40 and Aβ1–42) are produced through sequential proteolytic cleavage of the 
amyloid precursor protein (APP) by β- and γ-secretases. However, studies of autopsy brain samples from AD patients have 
demonstrated that a large fraction of insoluble Aβ peptides are truncated at the N-terminus, with Aβ4–x peptides being 
particularly abundant. Aβ4–x peptides are highly aggregation prone, but their origin and any proteases involved in their 
generation are unknown. We have identiﬁed a recognition site for the secreted metalloprotease ADAMTS4 (a disintegrin 
and metalloproteinase with thrombospondin motifs 4) in the Aβ peptide sequence, which facilitates Aβ4–x peptide genera-
tion. Inducible overexpression of ADAMTS4 in HEK293 cells resulted in the secretion of Aβ4–40 but unchanged levels 
of Aβ1–x peptides. In the 5xFAD mouse model of amyloidosis, Aβ4–x peptides were present not only in amyloid plaque 
cores and vessel walls, but also in white matter structures co-localized with axonal APP. In the  ADAMTS4−/− knockout 
background, Aβ4–40 levels were reduced conﬁrming a pivotal role of ADAMTS4 in vivo. Surprisingly, in the adult murine 
brain, ADAMTS4 was exclusively expressed in oligodendrocytes. Cultured oligodendrocytes secreted a variety of Aβ species, 
but Aβ4–40 peptides were absent in cultures derived from  ADAMTS4−/− mice indicating that the enzyme was essential for 
Aβ4–x production in this cell type. These ﬁndings establish an enzymatic mechanism for the generation of Aβ4–x peptides. 
They further identify oligodendrocytes as a source of these highly amyloidogenic Aβ peptides.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disorder and is responsible for an estimated 60–80% 
of all dementia cases [1]. According to the amyloid hypoth-
esis, the disease process starts with the accumulation of 
amyloid-β (Aβ) peptides in the brain, which form neurotoxic 
oligomers and insoluble amyloid plaques and trigger detri-
mental downstream events including Tau aggregation and 
chronic inﬂammation [67]. This chain of events is strongly 
supported by the genetic and biochemical analyses of rare, 
familial forms of AD with early onset, in which modest 
overproduction of Aβ peptides in the brain is suﬃcient to 
cause the disease with complete penetrance [4]. Full-length 
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Aβ peptides (mainly Aβ1–40 and Aβ1–42) are generated 
through sequential processing of the amyloid precursor 
protein (APP) by the proteases β- and γ-secretase [14]. In 
this process, the cleavage of APP by the β-secretase BACE1 
is the rate-limiting step for the production of Aβ peptides 
with an aspartate residue (Asp) at position 1 [78]. However, 
biochemical studies have revealed that a substantial frac-
tion of Aβ peptides extracted from autopsy brain samples 
of AD patients did not start with an Asp but were truncated 
at the N-terminus. Already in their seminal study in 1985, 
Masters et al. had demonstrated by N-terminal sequencing 
analysis that only around 10% of the formic acid extract-
able Aβ peptides began with an Asp while > 60% started 
with a phenylalanine residue (Phe) at position 4 [48]. While 
Aβ peptides truncated at various N-terminal residues have 
been detected in brain tissue and cerebrospinal ﬂuid sam-
ples of AD patients [6, 40], subsequent studies have largely 
conﬁrmed that Aβ4–42 and peptides with a pyroglutamate 
modiﬁcation at position 3 (AβpE3–42) are particularly abun-
dant [45, 50, 51, 58, 59, 68]. Recently, two studies reported 
novel Aβ4–x-speciﬁc antibodies and the consistent ﬁnding 
that in the brains of AD patients and mouse models Aβ4–x 
peptides were largely conﬁned to amyloid plaque cores, 
which are composed of the most insoluble, ﬁbrillar Aβ 
peptides in β-sheet conformation [11, 79]. In accordance, 
biophysical studies have demonstrated that Aβ4–x pep-
tides rapidly assembled into soluble oligomers and ﬁbrillar, 
high-molecular-weight aggregates [7, 11, 56]. Intriguingly, 
a comparison of the aggregation properties of Aβ1–40 and 
Aβ4–40 showed that the latter formed trimers and thioﬂavin-
T-binding aggregates almost instantly [11]. Thus, trunca-
tion of the ﬁrst three amino acids might therefore convert 
Aβ1–40 peptides, which are highly abundant in AD brains 
but have only limited tendency to aggregate, into a more 
pathogenic species. In vitro, Aβ4–40 and Aβ4–42 peptides 
were toxic to primary neurons with eﬀect sizes comparable 
to Aβ1–42 [7, 56]. Finally, expression of Aβ4–42 in trans-
genic mice resulted in age-dependent spatial memory deﬁ-
cits with a severe 50% neuron loss in the hippocampus at 
12 months of age [7].
The biophysical properties, distribution, and toxicity of 
Aβ4–x peptides point towards an important role for this Aβ 
species in the pathogenesis of AD. However, while these 
N-truncated peptides were detected more than 30 years ago, 
any proteases involved in their generation have remained 
elusive. In this study, we show that cleavage of APP within 
the Aβ peptide sequence by the secreted metalloprotease 
ADAMTS4 (a disintegrin and metalloproteinase with 
thrombospondin motifs 4) resulted in the release of Aβ4–x 
peptides both in vitro and in vivo. ADAMTS4 belongs to a 
family of  Zn2+-metalloproteases with a major role in extra-
cellular matrix (ECM) remodeling, e.g., during morphogene-
sis and angiogenesis [3, 38, 73, 74]. One of its substrates, the 
hyaluronan-binding proteoglycan aggrecan, is abundantly 
present in the articular cartilage, and ADAMTS4 has been 
linked to osteo- and rheumatoid arthritis [60, 71, 75]. We 
further demonstrate in the present study that Aβ4–x produc-
tion was not dependent on prior cleavage of APP by BACE1, 
and that puriﬁed ADAMTS4 was able to convert Aβ1–40 
into Aβ4–40 peptides, indicating that Aβ4–x peptides might 
be generated both within the cell and in the extracellular 
space. Immunohistochemistry in reporter mice demonstrated 
that in the adult mouse brain ADAMTS4 expression was 
restricted to oligodendrocytes. In agreement, white matter 
structures in aged 5xFAD mice showed abundant immuno-
reactivity for Aβ4–x peptides, which was absent in 5xFAD/
ADAMTS4−/− mice. In summary, we report an enzymatic 
mechanism for the generation of Aβ4–x peptides and the 
unexpected ﬁnding that oligodendrocytes are a source of 
these highly amyloidogenic peptides.
Materials and methods
Antibodies
The following primary antibodies were used in this study: 
anti-APP antibodies: CT-15 (rabbit pAb raised against the 
C-terminal 15 amino acids of human APP, 1:3500 immuno-
blotting, 1:500 immunocytochemistry) [77]; 22C11 (mouse 
mAb raised against residues 66–81 of human APP, 1:1000, 
kindly provided by Dr. Stefan Kins, University of Kaiser-
slautern, Germany) [66]; IG7/5A3 (mouse mAbs recog-
nizing non-overlapping epitopes of APP between residues 
380–665, 1:1000) [77]; 6A1 (mouse mAb recognizing the 
C-terminal neoepitope generated by β-secretase cleavage 
of Swedish APP, 1:50, IBL Cat. No. 10321); anti-APPs-β 
(rabbit pAb recognizing the C-terminal neoepitope gener-
ated by β-secretase cleavage of wild-type APP, 1:50, IBL 
Cat. No. 18957); anti-APP (rabbit pAb raised against res-
idues 756–770 of rat APP, 1:500, Synaptic Systems Cat. 
No. 127003). Anti-Aβ antibodies: IC16 (mouse mAb that 
preferentially detects Aβ peptides starting with Asp in posi-
tion 1) [2]; 029-2 (guinea pig pAb that exclusively detects 
Aβ4–x with Phe in position 4, 1:500 immunohistochemis-
try) [79]; BAP-24 (Aβ40 C-terminus-speciﬁc mouse mAb) 
[24]; BAP-29 (Aβ38 C-terminus-speciﬁc mouse mAb) [24]; 
BAP-15 (Aβ42 C-terminus-speciﬁc mouse mAb) [8, 24]; 
80C2 (mouse mAb against Aβ residues 1–5, 1:500, Synaptic 
Systems Cat. No. 218231); 4G8 (mouse mAb against Aβ 
residues 17–24, BioLegend Cat. No. 800701); D3E10 (rabbit 
mAb speciﬁc for the C-terminus of Aβx–42 peptides, 1:500, 
Cell Signaling Cat. No. 12843). Other antibodies: anti-V5 
Tag (mouse mAb, 1:500 immunoblotting, 1:250 immuno-
cytochemistry, ThermoFisher Scientiﬁc Cat. No. R960-25); 
anti-CNPase (mouse mAb, 1:1000; Sigma-Aldrich Cat. No. 
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C5922); anti-β-gal (rabbit pAb, 1:500, Millipore Cat. No. 
AB986); anti-GFAP (rabbit pAb, 1:500; DAKO Cat. No. 
Z0334); anti-Iba1 (guinea pig pAb, 1:300; Synaptic Sys-
tems Cat. No. 234004); anti-MAP2 (guinea pig pAb, 1:500, 
Synaptic Systems Cat. No. 188004); anti-Actin (rabbit pAb, 
1:2000, Sigma-Aldrich Cat. No. A2066); anti-calnexin (rat 
mAb, 1:250, BioLegend Cat. No. 699401); anti-TGN46 
(sheep pAb, 1:100, Bio-Rad Cat. No. AHP500G); anti-
Rab11 (goat pAb, 1:100, Santa Cruz Biotechnology).
Generation of cell lines with doxycycline-inducible 
ADAMTS4 expression
Cell lines with inducible ADAMTS4 expression based on 
HEK293 cells were generated using a lentiviral tetracy-
cline-controlled expression system. The expression system 
was a gift by Dr. Eric Campeau and consisted of the len-
tiviral expression vectors pLenti CMVtight Hygro DEST 
(Addgene plasmid#26433) and pLenti CMV rtTA3 Blast 
(Addgene Plasmid #26429) encoding the reverse tetracy-
cline-controlled transactivator 3 (rtTA3). Full-length human 
ADAMTS4 with a C-terminal V5-tag was cloned into pLenti 
CMVtight Hygro DEST by Gateway cloning (ThermoFisher 
Scientiﬁc). Viral particles were produced in 293FT cells 
using a third-generation lentivirus packaging system [20]. 
To generate double-stable cell lines expressing both rtTA3 
and tetracycline-inducible ADAMTS4, either HEK293 
cells with endogenous APP expression, or HEK293 cells 
with stable overexpression of the human APP695 isoform, 
or HEK293 cells with stable overexpression of the human 
APP695 isoform containing the “Swedish” double-mutation 
(the APP-overexpressing cell lines were a gift of Dr. Edward 
Koo, UC San Diego, USA) were ﬁrst infected with lentiviral 
particles expressing rtTA3 and a stable mass culture was 
selected with blasticidin. Subsequently, rtTA3 expressing 
cells were infected with ADAMTS4 lentiviral particles and 
stable clones were selected with hygromycin. Double-stable 
cell lines were maintained in antibiotic selection medium 
containing DMEM with 10% FCS (v/v), 1% sodium pyru-
vate (v/v), 100 U/ml penicillin/streptomycin, blasticidin, 
and hygromycin (all media components from ThermoFisher 
Scientiﬁc).
Immunoblotting
Cultured cells were lysed in Nonidet P40 buﬀer (50 mM 
Tris–HCl pH 7.8, 150 mM NaCl, 1% NP40 (v/v), 0.02% 
 NaN3 (w/v), with cOmplete protease inhibitor cocktail 
(Roche Diagnostics)) and total protein concentrations were 
determined with a BCA Protein Assay Kit (ThermoFisher 
Scientiﬁc). Equal amounts of protein were separated by 7% 
or 12% Bis–Tris SDS-PAGE and transferred onto PVDF 
membranes (Millipore) by electroblotting. The membranes 
were blocked with 3% gelatin from cold water ﬁsh skin 
(w/v) in PBS for 1 h at RT, and then incubated overnight 
at 4 °C with the primary antibody diluted in TBST (25 mM 
Tris, 137 mM NaCl, 2.7 mM KCl, 0.1% Tween-20 (v/v), 
pH 7.4). Subsequently, a secondary antibody labeled with 
a near-infrared ﬂuorescent dye (IRDye 800CW goat-anti-
mouse IgG or anti-rabbit IgG, LI-COR Biosciences) diluted 
in TBST was added and incubated for 1 h at RT. Fluores-
cence signals were detected with the Odyssey CLx Imaging 
System and quantiﬁed using the Image Studio Software 2.1 
(LI-COR Biosciences).
Aβ enzyme-linked immunosorbent assays
Aβ levels in brain extracts and conditioned tissue culture 
supernatants were determined using specific sandwich 
enzyme-linked immunosorbent assays (ELISA) as described 
[29, 79]. Standard curves were generated with synthetic Aβ 
peptides (JPT). To detect full-length Aβ1–38, Aβ1–40, and 
Aβ1–42 peptides, monoclonal antibody IC16 was used as a 
capture antibody and combined with Aβ C-terminus-speciﬁc 
detection antibodies. To detect N-truncated Aβ4–40 pep-
tides, the Aβ40 C-terminus-speciﬁc antibody BAP-24 was 
used as a capture antibody and combined with the Aβ4–x-
speciﬁc antibody 029-2 as a detection antibody. 96-well 
high-binding microtiter plates (Greiner Bio-One) were incu-
bated overnight at 4 °C with the capture antibodies in PBS, 
pH 7.2. After excess capture antibody was removed, freshly 
diluted brain samples, tissue culture media or Aβ peptide 
standards (in PBS, 0.05% Tween-20 (v/v), 1% BSA (w/v)) 
were added. Then, the detection antibodies labeled with 
horseradish peroxidase using the Pierce EZ-Link Plus Acti-
vated Peroxidase kit (ThermoFisher Scientiﬁc) and diluted 
in PBS, 0.05% Tween-20 (v/v), 1% BSA (w/v) were added 
to each well and incubated overnight at 4 °C. Plates were 
washed three times with PBS containing 0.05% Tween-20 
(v/v) and once with PBS. Subsequently, 50 μl of trimethylb-
enzidine ELISA peroxidase substrate (ThermoFisher Sci-
entiﬁc) was added and incubated for 1–5 min at RT in the 
dark. The reaction was terminated by adding 50 μl of 2 M 
 H2SO4, and the absorbance was recorded using a Paradigm 
microplate reader (Beckman Coulter) at 450 nm.
Immunoprecipitation/mass spectrometry analysis 
of secreted Aβ peptides
Mass spectrometry analysis of Aβ peptides was performed 
as previously described [18, 21]. Conditioned cell culture 
media were collected, cleared by centrifugation, and incu-
bated overnight at 4° C with antibody 4G8 (1 μg/ml) and 
30 μl of protein G (Sigma-Aldrich) to precipitate Aβ. The 
beads were washed 3 times with washing buﬀer (50 mM 
HEPES, 150 mM NaCl, 0.1% n-octyl-β-d-glycopyranoside 
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(w/v); pH 7.4), and immunoprecipitated proteins were eluted 
with triﬂuoroacetic acid (1%):acetonitrile:H2O (1:20:20). 
The elution was then mixed at a volume ratio of 1:1 with 
saturated α-cyano-4-hydroxycinnamic acid for the analysis 
by MALDI mass spectrometry in reﬂectron mode.
In vitro digest of synthetic Aβ1–40/Aβ1–42 peptides 
with purified ADAMTS4
To investigate whether Aβ1–40 and Aβ1–42 peptides could 
serve as substrates for ADAMTS4, two diﬀerent in vitro 
digest assays with puriﬁed ADAMTS4 were performed. 
In the ﬁrst assay, mature, catalytically active ADAMTS4 
was immunoprecipitated from culture supernatants of 
HEK293 cells with DOX-inducible expression of V5-tagged 
ADAMTS4 (HEK–TetOn–ADAMTS4 cells). Anti-V5 tag 
antibodies were coupled to magnetic M-280 Dynabeads 
(ThermoFisher Scientiﬁc) according to the manufacturer’s 
instructions. 25 μl of antibody coupled beads were incubated 
with 1 ml of conditioned cell culture supernatant for 2 h at 
RT. The beads were immobilized with a magnet, washed 
twice with PBS containing 0.1% BSA (w/v), and then incu-
bated with 350 μl of DMEM containing 15 ng of synthetic 
Aβ1–40 peptides (JPT Peptide Technologies) for 24 h at 
37 °C. The beads were removed and the supernatant was 
stored at -80 °C prior to ELISA analysis of Aβ4–40 levels. 
In the second assay, a recombinant, catalytically active frag-
ment of human ADAMTS4 was used  (Phe213-Cys685, R&D 
Systems). 1 μg of the recombinant ADAMTS4 was pre-incu-
bated for 20 min at 37 °C in assay buﬀer (50 mM HEPES, 
50 mM NaCl, 1 mM  CaCl2, 0.05% Brij-35, pH 7.5) in the 
presence or absence of 10 μM of the broad-spectrum met-
alloprotease inhibitor batimastat (BB-94, Sigma-Aldrich). 
The reaction was started by the addition of 25 ng synthetic 
Aβ1–42 peptides (JPT Peptide Technologies) in a total vol-
ume of 300 μl assay buﬀer. The reaction mixture was incu-
bated for 24 h at 37 °C, and the resulting Aβ peptide species 
were analyzed by immunoprecipitation followed by MALDI 
mass spectrometry.
Animals
The generation of 5xFAD mice (Tg6799) has been described 
[54]. 5xFAD mice overexpress the human APP695 isoform 
carrying the Swedish, Florida and London mutations, and 
human presenilin-1 carrying the M146L and L286V muta-
tions, both under the control of the murine Thy1-promoter. 
5xFAD mice have been backcrossed for more than 10 gen-
erations to C57Bl/6J wild-type mice from the Jackson Labo-
ratory (Bar Harbor, ME, USA) and were maintained on a 
C57BL/6J genetic background as a heterozygous transgenic 
line.  ADAMTS4+/− mice were obtained from the Jackson 
Laboratory (Strain #005770), and maintained on a C57BL/6J 
background. Detailed genotyping information is available 
at https ://www.jax.org/strai n/00577 0.  ADAMTS4+/− mice 
were crossed with 5xFAD mice to ﬁnally obtain heterozy-
gous 5xFAD mice on a homozygous ADAMTS4 KO back-
ground (5xFAD/ADAMTS4−/−). All animals were housed in 
a 12 h/12 h light–dark cycle with food and water ad libitum.
Brain tissue preparation
Mice were killed via  CO2 anesthetization followed by cer-
vical dislocation. For biochemical studies, frozen brain 
hemispheres were weighed and sequentially extracted. 
First, brains were homogenized in 700 μl of TBS (120 mM 
NaCl, 50 mM Tris, pH 8.0, with cOmplete protease inhibi-
tor cocktail) per 100 mg of tissue using a Dounce homog-
enizer (800 rpm). The resulting solution was centrifuged 
at 17,000 xg for 20 min at 4 °C. The pellet was dissolved 
in 800 μl of 2% SDS (w/v) in  ddH2O and sonicated, fol-
lowed by centrifugation at 17,000 xg for 20 min at 4 °C. The 
supernatant containing SDS-soluble proteins was incubated 
while rotating with 250 U of benzonase (Sigma-Aldrich) 
for 10 min at RT. Both TBS and SDS brain fractions were 
stored at − 80 °C before use for Western blotting or ELISA 
analysis. For immunohistochemistry, brains were dissected, 
immersion-ﬁxed in 4% phosphate-buﬀered formalin at 4 °C, 
dehydrated in a series of alcohols and embedded in paraﬃn.
Immunohisto- and immunocytochemistry
Immunohistochemistry was performed on 4 μm sagittal 
brain paraﬃn sections. After treatment with 0.3%  H2O2 (v/v) 
in PBS to block endogenous peroxidases, antigen retrieval 
was achieved by boiling sections in 0.01 M citrate buﬀer, pH 
6.0, followed by 3 min incubation in 88% formic acid. Non-
speciﬁc binding sites were blocked by treatment with skim 
milk and fetal calf serum in PBS. Sections were incubated 
with primary antibodies overnight at RT. For conventional 
immunostaining, biotinylated secondary anti-guinea pig 
(1:200; Dianova) or anti-mouse (DAKO) antibodies were 
used, and staining was visualized using the ABC method 
with a Vectastain Elite kit (Vector Laboratories) and diam-
inobenzidine (DAB) as a chromogen. Counterstaining was 
carried out with hematoxylin. For immunofluorescence 
labeling, corresponding ﬂuorescent secondary antibodies 
(1:750; Invitrogen or ThermoFisher Scientiﬁc) in combi-
nation with 4ƍ,6-diamidin-2-phenylindol (DAPI) were used. 
Images of DAB-stained sections were taken using a BX-51 
microscope (Olympus) with a Moticam Pro 282 camera 
(Motic) and analyzed using ImageJ 1.47b software (http://
image j.nih.gov/ij). Fluorescent images were recorded using 
a Nikon TiE microscope (Nikon) and analyzed with NIS Ele-
ments imaging software (Nikon). For immunocytochemistry, 
HEK–APP695sw/TetOn–ADAMTS4 cells were seeded on 
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poly-L-lysine (Sigma-Aldrich) coated glass coverslips, and 
ADAMTS4 expression was induced with DOX for 24 h. 
Cells were ﬁxed with 4% PFA (w/v) in  ddH20 for 10 min, 
permeabilized with 1% saponin (w/v) in TBS for 20 min, and 
blocked with 5% BSA (w/v) in TBS for 1 h, all at RT. To 
reduce cross reactions, instead of applying all primary and 
all secondary antibodies at the same time, primary antibod-
ies were applied one after another followed by their respec-
tive ﬂuorophore-tagged secondary antibodies. Each antibody 
was applied in 4% BSA (w/v) in TBS for 1 h. The follow-
ing secondary antibodies were used: Alexa Fluor 488 goat-
anti-rat (1:1000, ThermoFisher Scientiﬁc Cat. No. A11006); 
Alexa Fluor 546 goat-anti-rabbit (1:1000, ThermoFisher Sci-
entiﬁc Cat. No. A11071); Alexa Fluor 647 goat-anti-mouse 
(1:500, ThermoFisher Scientiﬁc Cat. No. A21235); Alexa 
Fluor 488 goat-anti-rabbit (1:1000, ThermoFisher Scien-
tiﬁc Cat. No. A11070); Alexa Fluor 594 goat-anti-mouse 
(1:500, ThermoFisher Scientiﬁc Cat. No. A11005); Cy3 
donkey-anti-sheep (1:500, Jackson ImmunoResearch Cat. 
No. 713-165-147); Cy3 donkey-anti-rabbit (1:500, Jackson 
ImmunoResearch Cat. No. 711-165-152); Cy5 donkey-anti-
goat (1:200, Jackson ImmunoResearch Cat. No. 705-175-
147); Cy2 donkey-anti-mouse (1:100, Jackson ImmunoRe-
search Cat. No. 715-225-151). Coverslips were mounted on 
glass slides with ProLong Gold Antifade Mountant with 
DAPI (ThermoFisher Scientiﬁc), cured for 24 h at RT in the 
dark, and analyzed with a LSM 710 confocal laser-scanning 
microscope (Zeiss).
Culture and differentiation of murine 
oligodendrocyte precursor cells (OPCs)
OPCs were prepared from whole brains of newborn (P1–P3) 
 ADAMTS4−/− KO or C57Bl/6J wild-type mice. Meninges 
were removed, brains were disintegrated with a scalpel, and 
pooled from animals with the same genotype. Brain tissue 
was further dissociated with the Neural Tissue Dissocia-
tion Kit, and  A2B5+ glial-restricted progenitors were iso-
lated by labeling with anti-A2B5 microbeads and magnetic 
enrichment using MS columns and a MiniMACS Separa-
tor according to the manufacturer’s instructions (Miltenyi 
Biotec). 1.5 × 106 progenitor cells were seeded on poly-
L-lysine coated 10 cm dishes and cultured in proliferation 
medium (DMEM/F12 without glutamine, 1× B-27 supple-
ment without vitamin A, 1× GlutaMAX, 100 U/ml penicil-
lin/streptomycin, 20 ng/ml each of mouse FGF-b and mouse 
PDGF-AA, all media components from ThermoFisher Sci-
entiﬁc, growth factors from ImmunoTools). Conﬂuency 
was kept below 50% and cells were passaged approximately 
every 4 days after dissociation of the cell monolayer with 
accutase (Sigma-Aldrich). For differentiation of OPCs, 
cells were switched to diﬀerentiation medium (same media 
components, except 1× B-27 with vitamin A, and without 
growth factors but instead supplemented with 40 ng/ml each 
of L-thyroxine  (T4) and triiodo-L-thyronine  (T3), Sigma-
Aldrich) for 1–5 days.
Adenovirus construction and infection of OPCs
Adenoviral vector construction was performed as previously 
described [46] with the following modiﬁcations: a cDNA 
encoding human APP695sw was cloned into the pAdTrack-
CMV shuttle vector (kindly provided by Dr. Bert Vogelstein, 
Johns Hopkins University, Addgene Plasmid #16405) using 
NotI/HindIII restriction sites. This shuttle vector incorpo-
rates a GFP marker and was transformed into AdEasier-1 
cells (derivative of BJ5183 cells containing the adenoviral 
backbone plasmid pAdEasy-1, Addgene bacterial strain 
#16399), which were made chemically competent by stand-
ard methods, to obtain recombinant adenovirus plasmids by 
homologous recombination. The recombinant adenovirus 
plasmids were packaged in HEK293 cells to obtain a low 
titer adenovirus preparation, which was further ampliﬁed 
and puriﬁed by a commercial vendor (GeneCust). To deter-
mine the functional titer of the adenovirus preparation, Hela 
cells were seeded in 6-well plates at a density of 70,000 cells 
per well. Serial dilutions of the adenovirus stock were pre-
pared in 1 ml DMEM growth medium and used to infect the 
cells for 3 h. After 24 h, the percent of ﬂuorescent-positive 
cells was determined using a Neubauer cell counting cham-
ber. To calculate the transduction units (TU) per ml, the fol-
lowing formula was used: (total number of cells transduced x 
percent ﬂuorescent cells x dilution factor)/transduction vol-
ume in ml. The assay was repeated three times and the aver-
age functional titer of the adenovirus stock was determined 
to be  5x108 TU/ml. For adenoviral transduction,  4x106 OPCs 
were seeded on poly-L-lysine coated 10 cm culture dishes in 
proliferation medium. The following day, cells were infected 
with 0.5 TU of adenovirus per cell for 4 h. 24 h after the 
infection, 4 ml of fresh proliferation medium were added 
and conditioned for another 24 h prior to ELISA and mass 
spectrometry analysis of Aβ levels.
Quantitative PCR
For mRNA expression analysis, total RNA was isolated from 
primary oligodendrocyte cultures at diﬀerent time points 
after initiation of diﬀerentiation using the ReliaPrep RNA 
Cell Miniprep System (Promega) according to the manu-
facturer’s instructions. First-strand cDNA was synthesized 
from 1 μg RNA by reverse transcription in a ﬁnal volume 
of 20 μl 1 x M-MLV reverse transcriptase reaction buﬀer 
(Promega) containing 1.25 μM random hexamers (Ther-
moFisher Scientiﬁc), 0.5 mM dNTPs (ThermoFisher Sci-
entiﬁc) and 200 units M-MLV (H–) reverse transcriptase 
(Promega). The mixture was incubated at 25 °C for 10 min, 
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at 40 °C for 50 min, and at 70 °C for 15 min. For quantitative 
PCR analysis, the Platinum qPCR Super Mix (ThermoFisher 
Scientiﬁc) based on the ﬂuorescent nucleic acid dye SYBR 
Green was used. 10 μl of the SYBR Green Mix, 500 nM 
of each primer, and 0.5 μl ROX reference dye were mixed 
and adjusted with RNase-free water to a ﬁnal volume of 
17 μl. 3 μl of the diluted cDNA (1:5 in RNase-free water) 
were added and the reaction mixture was transferred into 
a fast optical 96-well reaction plate (Applied Biosystems). 
Quantitative PCR was performed in a StepOnePlus Real-
Time PCR System (Applied Biosystems) using the following 
program: 95 °C for 10 min followed by 40 cycles of repeated 
denaturation and hybridization/elongation at 95 °C for 15 s 
and 60 °C for 1 min. The relative gene expression levels 
were calculated with the StepOnePlus Software 2.0 using 
the  2−ΔΔCT-method. GAPDH served as the housekeeping 
gene, and the expression levels were normalized to the val-
ues of non-diﬀerentiated oligodendrocytes at day 0. Primer 
sequences are available upon request.
Statistical analysis
Analyses were performed using Prism 5 (GraphPad Soft-
ware), and data are represented as mean ± SD. Comparisons 
between two groups were performed by unpaired t test, three 
or more groups were analyzed by one-way ANOVA followed 
by the Tukey’s post hoc test.
Results
Proteolytic cleavage of APP by ADAMTS4 generates 
N-truncated Aβ4–x peptides
By inspecting the N-terminal region of the Aβ peptide 
sequence within APP, we noticed that it contains two puta-
tive cleavage sites for the secreted zinc-metalloprotease 
ADAMTS4. Previously, through the screening of peptide 
libraries, a 7-amino acid recognition motif for ADAMTS4 
was deﬁned as E-(AFVLMY)-X(0,1)- (RK)-X(2,3)-(ST)-
(VYIFWMLA) with Glu at the P1 position [27]. This motif 
is partially conserved in the Aβ peptide sequence starting 
with the Glu residues 3 and 11 (Fig. 1a). Therefore, sequen-
tial cleavage of APP by ADAMTS4 and γ-secretase could 
potentially result in N-truncated Aβ peptides, e.g., Aβ4–40 
and Aβ12–40. To test this hypothesis in a cellular system 
that allows careful adjustment of ADAMTS4 expression, 
we generated HEK293 cells with stable co-expression of 
Swedish mutant human APP695 and doxycycline (DOX)-
inducible V5-tagged human ADAMTS4 (HEK-APP695sw/
TetOn-ADAMTS4 cells). DOX-induced single-cell clones 
displayed near equal expression of the immature pro-
form and the furin-processed, catalytically active form of 
ADAMTS4 in cell lysates and in culture media [76], with 
slight background expression in non-induced cells (Fig. 1b). 
To examine whether ADAMTS4 overexpression would 
aﬀect the secretion of full-length Aβ peptides with an intact 
N-terminus (Aβ1–x), Aβ levels in conditioned culture super-
natants were measured with a sandwich ELISA system that 
combined monoclonal antibody IC16, which preferentially 
detects Aβ peptides starting with Asp at position 1, with Aβ 
C-terminus-speciﬁc antibodies [2, 24]. In agreement with 
the predicted ADAMTS4 cleavage sites, measurements of 
Aβ1–40, Aβ1–42, and Aβ1–38 levels did not show diﬀer-
ences between DOX-induced ADAMTS4 expressing and 
non-induced control cells for three independent cell clones 
(Fig. 1c). Next, the secreted Aβ peptides were analyzed by 
MALDI-TOF mass spectrometry, which allowed detection 
of all Aβ peptides including N- and C-truncated species for 
which no speciﬁc antibodies are available. Mass spectra 
from culture supernatants of DOX-induced cells showed 
clear peaks for Aβ4–40 and Aβ12–40, providing qualita-
tive support that ADAMTS4 can generate Aβ4–x peptides 
and that the second, less-preserved recognition site starting 
with Glu11 is also cleaved in this ADAMTS4 overexpres-
sion system leading to the secretion of Aβ12–40 peptides 
(Fig. 1d). Due to the diﬀerential ionization properties of 
similar peptides, the quantitative analysis of MALDI-TOF 
measurements is limited and the peak heights in the mass 
spectra do not correspond to the abundance of individual 
peptides [9]. To obtain quantitative data and to conﬁrm these 
results with an independent method, culture supernatants 
were analyzed with a sandwich ELISA that combined an 
Aβ40 C-terminus-speciﬁc antibody with the polyclonal anti-
body 029-2, which exclusively detects Aβ4–x peptides with 
Phe at position 4, as described [79]. Measurements revealed 
around 2 ng/ml of Aβ4–40 peptides in culture supernatants 
after induction of ADAMTS4 expression, while non-induced 
control cells showed no background signal (Fig. 1e). In sum, 
these data indicated that ADAMTS4 is able to cleave APP 
at the predicted sites, resulting in the secretion of Aβ4–40 
and Aβ12–40 peptides.
Prior cleavage of APP by BACE1 is not required 
for the generation of N-truncated Aβ4–x peptides, 
and recombinant Aβ1–x can serve as a substrate 
for ADAMTS4
The experiments shown above did not clarify whether 
ADAMTS4 by itself could cleave APP and generate Aβ4–x 
peptides within the cell, or whether ADAMTS4 might only 
remove the ﬁrst three amino acids from Aβ1–x peptides 
with an intact N-terminus, presumably in the extracellular 
space. To address this question, two sets of experiments 
were performed. First, we examined whether Aβ4–x pep-
tides could still be generated by ADAMTS4 in the presence 
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Fig. 1  ADAMTS4 generates N-truncated Aβ4–x peptides. a The 
N-terminal part of the Aβ peptide sequence is shown with the 
β-secretase cleavage site prior to Asp1 and the α-secretase cleav-
age site after Lys16. A recognition site for the metalloprotease 
ADAMTS4 starts with Glu3 and conforms entirely to the recognition 
motif as deﬁned by Hills et  al. with the exception of Gly9 [27]. A 
second putative recognition site starting with Glu11 is less preserved. 
b ADAMTS4 protein levels in HEK-APP695sw/TetOn-ADAMTS4 
cells. ADAMTS4 expression was induced with DOX (100  ng/ml) 
for 48 h and cell lysates and culture supernatants were analyzed by 
Western blotting with anti-V5 antibody. Three single-cell clones dis-
played near equal expression of both the pro-form (immature) and the 
catalytically active form (mature) of ADAMTS4. Mature ADAMTS4 
migrated below the 100  kDa molecular weight marker (M) consist-
ent with previous results [76]. c Measurement of Aβ1–x peptide 
levels in conditioned culture supernatants of HEK-APP695sw/
TetOn-ADAMTS4 cells. Aβ1–40, Aβ1–42, and Aβ1–38 levels were 
unchanged after induction of ADAMTS4 expression as compared to 
non-induced control cells. Three independent biological experiments 
for each cell clone (n = 3) with two technical replicates per experi-
mental condition were performed. d Mass spectrometry analysis of 
Aβ peptides in conditioned culture supernatants of HEK–APP695sw/
TetOn–ADAMTS4 cells. ADAMTS4 expression was induced with 
DOX and supernatants were immunoprecipitated with the monoclo-
nal anti-Aβ antibody 4G8 and analyzed by MALDI-TOF mass spec-
trometry. Spectra of non-induced control cells (-DOX) showed peaks 
for the common Aβ species such as Aβ1–40, Aβ1–42, and Aβ1–38. 
Only after induction of ADAMTS4 expression (+DOX), Aβ4–40 
and Aβ12–40 peptides were clearly detected while other Aβ species 
remained unchanged. Nearly identical spectra were acquired from 
three single-cell clones, and representative spectra are shown. The 
measured monoisotopic masses and the expected masses, and the 
primary amino acid sequences of the detected peptides are shown 
in Supplementary Table  4. e Robust levels of Aβ4–40 peptides 
were detected in culture supernatants of HEK–APP695sw/TetOn–
ADAMTS4 cells after induction of ADAMTS4 expression with no 
background in non-induced control cells. Three independent biologi-
cal experiments for each cell clone (n = 3) with two technical repli-
cates per experimental condition were performed
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of a potent β-secretase inhibitor. Treating HEK–APP695sw/
TetOn–ADAMTS4 cells with BACE inhibitor IV abolished 
Aβ1–40 peptides in culture supernatants with or without 
ADAMTS4 expression (Fig. 2a). However, analyzing the 
same culture supernatants with the Aβ4–40 speciﬁc ELISA 
showed that these N-truncated peptides were not reduced, 
indicating that Aβ4–x production was not dependent on 
BACE1 activity (Fig.  2a). Second, to explore whether 
ADAMTS4 would be able to convert Aβ1–x into Aβ4–x 
peptides, we established HEK293 cells with DOX-induc-
ible expression of V5-tagged ADAMTS4 (HEK-TetOn-
ADAMTS4), and immunoprecipitated ADAMTS4 from 
conditioned media with anti-V5 antibody. The immunopre-
cipitated mature, catalytically active form of ADAMTS4 
(Fig. 2b) was then incubated with recombinant Aβ1–40 
peptides in fresh culture medium for 24 h, and the gen-
eration of Aβ4–40 peptides was detected by ELISA. An 
approximately fivefold increase in Aβ4–40 levels was 
observed when ADAMTS4 was immunoprecipitated from 
DOX-induced cells as compared to non-induced control cells 
(Fig. 2b). To further prove that ADAMTS4 is the responsi-
ble enzyme activity and to demonstrate that recombinant 
Aβ1–42 could also serve as a substrate, we performed a 
cell-free in vitro assay followed by mass spectrometry anal-
ysis (Supplementary Fig. S1). After the co-incubation of 
recombinant ADAMTS4 with Aβ1–42 peptides, peaks cor-
responding to both Aβ4–42 and Aβ12–42 were observed 
in the mass spectra. Importantly, these peaks were not seen 
when enzyme and substrate were incubated in the presence 
of the broad-spectrum metalloprotease inhibitor batimastat 
(BB-94; 10 μM) (Supplementary Fig. S1). Taken together, 
these experiments demonstrated that ADAMTS4 was able to 
cleave APP and to generate Aβ4–x peptides within the cell 
without prior cleavage of APP by β-secretase. In addition, 
they showed that ADAMTS4 can convert Aβ1–x into Aβ4–x 
peptides, providing evidence that ADAMTS4 might truncate 
Aβ1–x peptides at the N-terminus in the extracellular space.
Proteolytic processing of APP by ADAMTS4 affects 
levels of its soluble ectodomain APPs
To assess whether ADAMTS4 might cleave APP outside 
of the Aβ region and aﬀect the levels of other APP metabo-
lites, cell lysates of DOX-induced HEK-APP695sw/TetOn-
ADAMTS4 cells and non-induced control cells were ana-
lyzed by Western blotting with antibody CT-15 against the 
last 15 C-terminal amino acids of APP (antibody epitopes 
are illustrated in Fig. 2c). No overt diﬀerences in the levels 
of full-length APP or the APP C-terminal fragments (APP-
CTFs) generated by β- or α-secretase were observed (Sup-
plementary Fig. S2a). However, in ADAMTS4 expressing 
cells a novel APP-CTF with a molecular weight between 
25-35  kDa was observed (Supplementary Fig. S2a). 
Moreover, closer inspection of APP levels showed a signiﬁ-
cant, greater than 50% reduction in the mature, glycosylated 
forms of APP localized to late compartments of the secre-
tory pathway and the cell surface [35], while the immature 
forms of APP remained unchanged (Supplementary Fig. 
S2b, c). Immunoﬂuorescence stainings demonstrated co-
localization of ADAMTS4 and APP with the Golgi marker 
TGN46 but not with the ER marker calnexin or the late 
endosome marker Rab11 (Supplementary Fig. S2d-e). 
Taken together, these ﬁndings suggested that ADAMTS4 
might cleave APP in the secretory pathway presumably in 
the Golgi compartment, with an additional cleavage site 
located in the APP ectodomain further N-terminal to the 
β-secretase cleavage site. Accordingly, we examined the 
levels of the soluble APP ectodomain (APPs) in culture 
supernatants with a set of antibodies spanning epitopes 
along the extracellular domain (Fig. 2c). Western blotting 
with antibody 22C11, which detects the N-terminus of APP 
(amino acids 66-81), showed reduced levels of full-length 
APPs in ADAMTS4 expressing cells (Fig. 2d). In addition, 
an approximately 20–30 kDa smaller APPs fragment was 
prominently detected in supernatants of DOX-induced cells, 
which appeared to correspond to the 25–35 kDa APP-CTF 
detected in cell lysates (Fig. 2d and Supplementary Fig. 
S2a). Antibodies IG7/5A3 against the mid-region of the 
APP ectodomain (amino acids 380–665) and 6A1, which 
detects the C-terminal neo-epitope generated by β-secretase 
cleavage of APP, conﬁrmed a strong reduction in APPs and 
APPs-β levels after induction of ADAMTS4 expression 
(Fig. 2d). However, no APPs band with faster mobility was 
detected likely because the antibody epitopes were removed 
from this C-terminally truncated APPs fragment (Fig. 2d). 
Very similar results were obtained in HEK293 cell lines 
with either stable overexpression of wild-type APP695 or 
endogenous APP expression, indicating that the Swedish 
mutation located just three amino acids N-terminal to the 
ﬁrst ADAMTS4 recognition site in the Aβ domain did not 
interfere with the proteolytic cleavage of APP by ADAMTS4 
(Supplementary Fig. S3). Overall, in ADAMTS4 expressing 
cells, a substantial reduction in APPs levels was observed, 
suggesting that ADAMTS4 might not only facilitate the 
generation of N-truncated Aβ4–x peptides but might also 
exert partial control over the levels of the soluble ectodo-
main APPs.
Genetic deletion of ADAMTS4 lowers Aβ4–x 
and increases APPs levels in vivo
To validate the relevance of ADAMTS4 for Aβ generation 
and APP processing in vivo,  ADAMTS4−/− knockout (KO) 
mice were crossed to the 5xFAD model of AD [54, 61]. 
Consistent with previous results [62], mass spectrometry 
analysis of Aβ peptide species in the brains of 12-month-old 
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Fig. 2  ADAMTS4 generates Aβ4–x peptides without prior cleavage 
of APP by BACE1, recognizes recombinant Aβ1–40 as substrate, and 
aﬀects APPs levels. a HEK-APP695sw/TetOn-ADAMTS4 cells were 
pre-treated with BACE1 inhibitor IV (1 μM) for 24 h. Subsequently, 
medium was changed and ADAMTS4 expression was induced with 
DOX for 24 h in the presence of the BACE1 inhibitor. Medium was 
changed again and conditioned for another 24  h in the presence of 
DOX and the BACE1 inhibitor. Finally, conditioned media were 
analyzed with Aβ1–40 or Aβ4–40-speciﬁc ELISA assays. In control 
experiments, cells were not treated with the BACE1 inhibitor, and/
or induction of ADAMTS4 expression was omitted. Consistent with 
the experiments shown in Fig.  1c, Aβ1–40 levels were not aﬀected 
by the induction of ADAMTS4 expression. In contrast, Aβ1–40 
peptides were completely abolished by treatment with the BACE1 
inhibitor. Aβ4–40 peptides were only detected after induction of 
ADAMTS4 expression but not in non-induced control cells. Concom-
itant inhibition of BACE1 did not reduce Aβ4–40 levels, indicating 
that ADAMTS4 was able to cleave APP and to generate Aβ4–x pep-
tides within the cell without prior cleavage of APP by BACE1. Three 
independent biological experiments for each cell clone (n = 3) with 
two technical replicates per experimental condition were performed. 
b ADAMTS4 was immunoprecipitated from conditioned culture 
supernatants of DOX-induced (48  h) or non-induced HEK–TetOn–
ADAMTS4 cells with anti-V5 antibody. These cells express endog-
enous APP and secrete only minor amounts of Aβ undetectable with 
our ELISA assays. The immunoprecipitated material was analyzed by 
Western blotting with anti-V5 antibody, which conﬁrmed the success-
ful immunoprecipitation of the mature, catalytically active form of 
ADAMTS4 from supernatants of DOX-induced cells. Immunoprecip-
itated ADAMTS4 was then incubated with recombinant Aβ1–40 for 
24 h, and the conversion of Aβ1–40 to Aβ4–40 peptides was meas-
ured by ELISA. An approximately ﬁvefold increase in Aβ4–40 lev-
els was observed with immunoprecipitated material from ADAMTS4 
expressing versus non-induced control cells. The Aβ4–40 signal in 
the control condition was likely due to slight background expression 
of ADAMTS4 in non-induced cells and further enrichment by immu-
noprecipitation. Three independent biological experiments (n = 3) 
with two technical replicates for each experimental condition were 
performed. Unpaired t test was used to compare the means *p < 0.05. 
c Schematic representation of APP and the antibody epitopes that 
were analyzed to investigate its proteolytic processing by ADAMTS4. 
d Levels of the soluble APP ectodomain APPs were reduced in 
ADAMTS4 expressing cells. HEK–APP695sw/TetOn–ADAMTS4 
cells were induced with DOX, and diﬀerent epitopes spanning the 
APP ectodomain were analyzed in culture supernatants. Western 
blotting with antibody 22C11 against the N-terminus of APP (upper 
panel) revealed a decrease in full-length APPs levels and an addi-
tional APPs fragment of approximately 70  kDa (marked with *) in 
all three ADAMTS4 expressing cell clones versus non-induced con-
trol cells. Western blotting with antibodies IG7/5A3 (middle panel) 
and 6A1 (lower panel), which recognize the mid-region of APP or 
the C-terminal neoepitope generated by β-secretase cleavage of APP, 
conﬁrmed a substantial reduction in full-length APPs and APPs-β 
levels after induction of ADAMTS4 expression. Three independent 
biological experiments were performed (n = 3), and one representa-
tive experiment is shown
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5xFAD mice showed clearly detectable Aβ4–40 and Aβ4–42 
peptides, demonstrating the suitability of the 5xFAD model 
and the age group (Supplementary Fig. S4). Hence, 5xFAD/
ADAMTS4−/− and 5xFAD/ADAMTS4+/+ mice were aged to 
12 months and TBS- and SDS-soluble brain fractions were 
analyzed by ELISA. Measurements of Aβ4–40 peptides 
in the SDS brain fractions demonstrated a signiﬁcant 50% 
reduction in 5xFAD/ADAMTS4−/− mice corroborating that 
ADAMTS4 is critical for Aβ4–x levels in vivo (Fig. 3a). 
In contrast, Aβ1–40 and Aβ1–42 levels in the SDS frac-
tions and Aβ1–42 levels in the TBS fractions were not dif-
ferent between the genotypes (Fig. 3b, d). As demonstrated 
in our previous study [79], the levels of the N-truncated 
Aβ4–40 peptides were low compared to full-length Aβ pep-
tides in 5xFAD mice. In the SDS-soluble brain fractions of 
12-month-old animals, Aβ4–40 levels were approximately 
70-fold and 1500-fold lower than Aβ1–40 and Aβ1–42 levels 
(Fig. 3a–c). Consistent with these results, no obvious dif-
ferences in the overall amyloid plaque load as determined 
by immunohistochemistry with antibodies against Aβ1–x 
or Aβx–42 peptides were observed between the genotypes 
(Supplementary Fig. S5a). Importantly, these results were 
conﬁrmed in a second independent cohort of animals aged 
to 15 months (Supplementary Fig. S5b-e). In addition, 
soluble and membrane-bound APP fragments were ana-
lyzed by Western blotting in the brains of 12-month-old 
mice. The levels of full-length APP in the SDS fractions 
were unchanged between the genotypes (Fig. 3e). How-
ever, a signiﬁcant 20–25% increase in APPs and APPs-β 
levels was observed in the TBS fractions of 5xFAD/
ADAMTS4−/− mice as compared to 5xFAD/ADAMTS4+/+ 
control animals (Fig. 3f, g). These results were consist-
ent with the tissue culture experiments, which had shown 
reduced APPs levels with overexpression of ADAMTS4 
(Fig. 2d), and indicated that ADAMTS4 might also partially 
control APPs levels in the brain.
ADAMTS4 generated Aβ4–x peptides in white 
matter fiber tracts and neuronal processes
Previously, Aβ4–x peptides have been localized to amyloid 
plaque cores and vascular amyloid deposits in the brains 
of AD patients and diﬀerent AD mouse models including 
5xFAD [11, 79]. Intriguingly, using the Aβ4–x-speciﬁc 
antibody 029-2, we discovered an additional pool of Aβ4–x 
peptides in white matter ﬁber tracts and neuronal processes 
of aged 5xFAD mice, which was dependent on the expres-
sion of ADAMTS4. Immunohistochemical analyses of 
12-month-old 5xFAD mice revealed abundant Aβ4–x pep-
tides within axon-rich ﬁber tracts such as the dorsal hip-
pocampal commissure and the dorsal fornix that co-localized 
with the axonal marker APP (Supplementary Fig. S6). In the 
corpus callosum, abundant dot-like immunoreactivity was 
detected, which was signiﬁcantly reduced in age-matched 
5xFAD/ADAMTS4−/− mice (Supplementary Fig. S7). Aged 
5xFAD mice also showed abundant Aβ4–x positive ﬁbers 
in cortical areas together with Aβ4–x positive extracellular 
amyloid deposits (Fig. 4a, b). In contrast, no such Aβ4–x 
positive cellular processes were detected in age-matched 
5xFAD/ADAMTS4−/− mice (Fig. 4c, d). Further analysis 
of the dorsal fornix demonstrated abundant co-localization 
of Aβ4–x peptides within ﬁbers positive for the oligoden-
drocyte marker 2ƍ, 3ƍ-cyclic nucleotide 3ƍ-phosphodiester-
ase (CNPase), an early myelin protein that continues to be 
expressed at high levels in the adult CNS [5] (Fig. 4e, f). 
This Aβ4–x immunoreactivity was completely absent in age-
matched 5xFAD/ADAMTS4−/− mice (Fig. 4g, h). In sum-
mary, these results indicated that ADAMTS4 contributes 
to a novel pool of Aβ4–x peptides localized to white matter 
structures and neuronal processes.
ADAMTS4 is exclusively expressed 
in oligodendrocytes and is essential for Aβ4–x 
peptide generation in primary oligodendrocyte 
cultures
The remarkable, ADAMTS4-dependent localization of 
Aβ4–x peptides to white matter ﬁber tracts and neuronal 
processes prompted us to investigate the expression of 
ADAMTS4 in the adult murine brain. Prior studies had 
provided conﬂicting results and evidence for ADAMTS4 
expression in both neurons and all glial cell types of the 
central nervous system (CNS) [19, 39, 43, 61, 69, 82]. We 
took advantage of the  ADAMTS4−/− KO mice, in which 
the ADAMTS4 gene locus was disrupted by insertion of a 
bacterial lacZ gene such that the endogenous ADAMTS4 
gene promotor would drive the expression of β-galactosidase 
(β-gal). This enabled us to examine the ADAMTS4 expres-
sion pattern by β-gal immunohistochemistry. In cortical 
brain sections of 6.5-month-old 5xFAD/ADAMTS4−/− mice, 
expression of β-gal did not co-localize with the neuronal 
marker MAP2, the astrocytic marker GFAP, or the micro-
glia marker Iba1 (Supplementary Fig. S8a-c). Instead, clear 
co-localization of β-gal positive cell nuclei with CNPase 
was observed, indicating that ADAMTS4 was exclusively 
expressed in the oligodendrocytic cell lineage (Supplemen-
tary Fig. S8d-f). Next, we studied the role of ADAMTS4 
in APP processing and Aβ generation speciﬁcally in oligo-
dendrocytes. Initially, to conﬁrm ADAMTS4 expression in 
oligodendrocytes, we extracted oligodendrocyte progenitor 
cells (OPCs) from whole brains of newborn wild-type mice 
and diﬀerentiated them in culture to mature oligodendro-
cytes over a period of 5 days. ADAMTS4 mRNA expression 
was detected by qPCR both in OPCs and mature oligoden-
drocytes with a clear trend for increased expression in the 
course of the diﬀerentiation process (Supplementary Fig. 
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Fig. 3  Genetic deletion of ADAMTS4 lowers Aβ4–x and increases 
APPs levels in  vivo. a Aβ4–40 levels were signiﬁcantly reduced 
in the SDS-soluble brain fractions of 12-month-old 5xFAD/
ADAMTS4−/− mice (n = 3) as compared to 5xFAD/ADAMTS4+/+ 
control animals (n = 3). b–d In contrast, Aβ1–40 (b) and Aβ1–42 (c) 
in the SDS fractions and Aβ1–42 (d) in the TBS fractions were not 
diﬀerent between the genotypes. Unpaired t test was used to com-
pare the means between the genotypes. **p < 0.01. e–g Full-length 
APP levels (e) in the SDS brain fraction as measured by Western 
blotting with antibody CT-15 were not diﬀerent between the geno-
types. Conversely, APPs (f) and APPs-β (g) levels in the TBS frac-
tions as measured by Western blotting with antibodies 22C11 and 
6A1 were signiﬁcantly increased in 5xFAD/ADAMTS4−/− mice as 
compared to 5xFAD/ADAMTS4+/+ control animals. Each Western 
blot was repeated three times and one representative blot is shown. 
For quantiﬁcation, APP signal intensities were measured, normal-
ized to actin levels, and averaged for the three technical replicates. 
Means were calculated for each genotype, and the values of the 
5xFAD/ADAMTS4+/+ control animals were set to 100%. 5xFAD/
ADAMTS4−/− (n = 3), 5xFAD/ADAMTS4+/+ (n = 3-4). Unpaired t 
test was used to compare the means between the genotypes. *p < 0.05. 
nTg, non-transgenic C57Bl/6 control mice
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S9a-c). Endogenous APP processing was then compared 
in OPC cultures from  ADAMTS4−/− KO and wild-type 
control mice. Full-length APP levels in cell lysates were 
unchanged between the genotypes (Fig. 5a). However, total 
APPs levels were more than threefold higher in conditioned 
media of  ADAMTS4−/− KO oligodendrocytes compared to 
wild-type cells (Fig. 5b), reﬂecting the increased APPs lev-
els in the brains of 5xFAD/ADAMTS4−/− mice. To enable 
Aβ measurements, OPC cultures from  ADAMTS4−/− KO 
and wild-type control mice were infected with an adenovi-
rus expressing human APP695sw, and conditioned media 
were analyzed by mass spectrometry. In the supernatants of 
wild-type oligodendrocytes, Aβ4–40 peptides were clearly 
detected alongside the more common species like Aβ1–40, 
Aβ1–42 and Aβ1–38. In contrast, the mass spectra acquired 
from  ADAMTS4−/− KO cells showed no peak corresponding 
to Aβ4–40 while the other Aβ species remained unchanged 
(Fig. 5c). To quantify these diﬀerences, conditioned media 
were analyzed with Aβ1–40 and Aβ4–40 speciﬁc ELISAs. 
Both wild-type oligodendrocytes and  ADAMTS4−/− KO 
cells secreted comparable amounts of Aβ1–40 peptides 
(Fig. 5d). However, in sharp contrast, Aβ4–40 peptides were 
only detectable in conditioned media of ADAMTS4 express-
ing wild-type oligodendrocytes, indicating that the enzyme 
was essential for the generation of Aβ4–x peptides in this 
cell type (Fig. 5e).
Discussion
N-truncated Aβ peptides, in particular Aβ4–x and pyrogluta-
mated AβpE3-42, are abundantly present in AD brains [45, 
51, 58], yet the molecular mechanisms of N-terminal residue 
removal are largely unknown. In this study, using cellular 
and in vivo models, we showed that Aβ4–x peptides can 
be generated by the secreted metalloprotease ADAMTS4. 
Intriguingly, ADAMTS4 was recently identiﬁed as a poten-
tial novel AD risk locus by two large-scale genome-wide 
association studies available in preprint form [31, 47]. Our 
ﬁndings connect ADAMTS4 to one of the core pathologi-
cal pathways in AD, APP processing and Aβ generation. 
Stable co-expression of APP and ADAMTS4 in HEK293 
cells facilitated the secretion of Aβ4–x and Aβ12–x pep-
tides, while Aβ1–x peptides with an intact N-terminus were 
not aﬀected. Importantly, this was conﬁrmed in model sys-
tems with endogenous ADAMTS4 expression and through 
genetic controls. In primary oligodendrocytes, ADAMTS4 
was essential for Aβ4–40 secretion, and Aβ4–40 levels were 
reduced in the brains of aged 5xFAD/ADAMTS4−/− mice. 
However, Aβ12–x peptides were neither secreted by oli-
godendrocytes nor detected in the brain tissue of 5xFAD 
mice. This indicated that the second putative ADAMTS4 
cleavage site in the Aβ sequence, which deviates from the 
proposed consensus sequence [27], was not recognized to 
Fig. 4  Aβ4–x peptides in neuronal processes and white matter ﬁber 
tracts. a, b Aβ4–x positive ﬁbers (arrows) were abundantly present in 
the cortex of 12-month-old 5xFAD mice. c, d Aβ4–x immunoreactive 
ﬁbers were not detected in age-matched 5xFAD/ADAMTS4−/− mice. 
e, f Prominent Aβ4–x immunoreactivity was present in CNPase-pos-
itive ﬁbers in the dorsal fornix (df) of 12-month-old 5XFAD mice. 
g, h This immunoreactivity was absent in age-matched 5xFAD/
ADAMTS4−/− mice. The images in the left panel show high-power 
magniﬁcations of the immunoﬂuorescence stainings on the right. 
Scale bars: a, c 50 μm; b, d 15 μm; e, g 100 μm; f, h 33 μm
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any measurable degree in cells with endogenous ADAMTS4 
expression, in agreement with the fact that Aβ12–x pep-
tides have not been detected in the human brain [51, 58]. 
APP is a type-1 transmembrane protein located in the secre-
tory pathway and at the cell surface, whereas ADAMTS4 
is a secreted soluble metalloprotease, which becomes acti-
vated in the trans-Golgi network but has its main substrates 
in the extracellular matrix [53, 76]. Hence, an intriguing 
question is the cellular compartment(s) in which enzyme 
and substrate meet to produce Aβ4–x peptides. Our data 
indicate that Aβ4–x peptide generation might occur both 
within the cell and in the extracellular space. Treatment of 
HEK293 cells co-expressing APP and ADAMTS4 with a 
BACE1 inhibitor reduced Aβ1–40 in culture supernatants 
to undetectable levels but had no eﬀect on Aβ4–40 levels. 
Under these conditions, Aβ4–40 could not have been gener-
ated through truncation of Aβ1–40 in the extracellular space. 
Instead, these Aβ4–40 peptides must have been generated 
intracellularly by ADAMTS4 cleavage of APP within the Aβ 
domain followed by γ-secretase cleavage, which in its cata-
lytically active form is also enriched in late compartments of 
the secretory pathway and at the cell surface [35]. However, 
in cell-free assays, ADAMTS4 was also able to generate 
Aβ4–40 and Aβ4–42 peptides by truncation of recombinant 
Aβ1–40/Aβ1–42, indicating that ADAMTS4 might also use 
Aβ1–x peptides generated by BACE1 as a substrate in the 
a c
b
d e
Fig. 5  ADAMTS4 is essential for Aβ4–x peptide generation and 
controls APPs levels in primary oligodendrocyte cultures. a-b 
Endogenous, full-length APP levels (a) were unchanged in oligo-
dendrocyte progenitor cells (OPCs) cultured from wild type ver-
sus  ADAMTS4−/− KO mice as measured by Western blotting with 
antibody CT-15. In contrast, APPs levels (b) were signiﬁcantly 
increased in conditioned media of  ADAMTS4−/− KO cultures com-
pared to wild-type OPC cultures as measured by Western blotting 
with antibody 22C11. The Western blots and the quantiﬁcations 
show the results of three independent biological experiments (n = 3). 
APP signal intensities were normalized to actin levels, while APPs 
signals were normalized to APP levels in the corresponding cell 
lysates. Means were calculated for each genotype, and the values 
of the  ADAMTS4+/+ control cells were set to 100%. Unpaired t test 
was used to compare the means between the genotypes. **p < 0.01. 
c Mass spectrometry analysis of Aβ peptide species in OPC cultures. 
The cells were infected with an adenovirus expressing APP695sw, 
and conditioned media were immunoprecipitated with anti-Aβ anti-
body 4G8 and analyzed by MALDI-TOF mass spectrometry. The 
mass spectra acquired from  ADAMTS4+/+ control cells displayed a 
peak corresponding to Aβ4–40 peptides (enlargement, black box), 
which was absent in the spectra generated from  ADAMTS4−/− KO 
cultures. Other Aβ species appeared unchanged between the geno-
types. Three independent biological experiments (n = 3) were per-
formed and representative mass spectra are shown. The measured 
monoisotopic masses and the expected masses, and the primary 
amino acid sequences of the detected peptides are shown in Supple-
mentary Table 2. d, e OPCs cultured from wild type or  ADAMTS4−/− 
KO mice were infected with the APP695sw adenovirus and condi-
tioned media were analyzed with Aβ1–40 or Aβ4–40 speciﬁc ELISA 
assays. Cells from both genotypes secreted comparable amounts 
of Aβ1–40 peptides (d). In contrast, Aβ4–40 peptides (e) were only 
detectable in conditioned media of ADAMTS4 expressing wild-type 
OPCs but not in  ADAMTS4−/− KO cultures. The graphs depict the 
results of three independent biological experiments (Exp) (n = 3)
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extracellular space. In vivo, both of these mechanisms could 
apply. Co-expression of APP and endogenous ADAMTS4 
in oligodendrocytes was suﬃcient to generate Aβ4–x pep-
tides demonstrating that these cells could produce a fraction 
of the Aβ4–x peptides. Alternatively, ADAMTS4 might be 
secreted by oligodendrocytes and could process Aβ1–x in 
the extracellular space, or neuronal APP, which has been 
localized to the surface of axonal membranes [15]. Yet 
another possibility is that ADAMTS4 is secreted by oli-
godendrocytes and taken up by neurons through endocy-
tosis, leading to the processing of APP by ADAMTS4 in 
intracellular vesicular compartments. Indeed, in cartilage, 
it has been demonstrated that extracellular ADAMTS4 can 
be internalized via low density lipoprotein receptor-related 
protein (LRP1), which is abundantly expressed in neurons 
[57, 81]. Further studies are required to clarify this issue, 
but all three of these possibilities conform to our immuno-
histochemical detection of Aβ4–x peptides in white matter 
structures and their co-localization with APP in ﬁber tracts 
of 5xFAD mice (see below).
In addition, ADAMTS4 consistently aﬀected the levels of 
the secreted ectodomain APPs, which has neurotrophic prop-
erties and was shown to rescue most of the phenotypic deﬁ-
cits in  APP−/− KO mice [53, 63]. ADAMTS4 overexpression 
strongly reduced APPs levels while conditioned media of 
 ADAMTS4−/− KO oligodendrocytes showed a substantial 
increase in APPs levels compared to wild-type cells. A less 
prominent but consistent increase in APPs levels was also 
detected in brain tissue of 5xFAD/ADAMTS4−/− mice, with 
the smaller eﬀect size likely reﬂecting the restricted expres-
sion of ADAMTS4 in the mouse brain. However, other APP 
processing changes seen in ADAMTS4 overexpressing cells 
such as changes in mature APP levels and the appearance 
of larger APP-CTF and smaller APPs fragments were not 
conﬁrmed in oligodendrocyte cultures or in vivo, indicating 
that they were likely overexpression artifacts. These results 
demonstrated that the eﬀects of ADAMTS4 are not limited 
to the generation of Aβ4–x peptides and that ADAMTS4 
might partially control APPs turnover. This was also remi-
niscent of ﬁndings with the membrane-bound metallopro-
tease meprin β, which has been implicated in the generation 
of N-truncated Aβ2–x peptides. Like ADAMTS4, meprin 
β has been shown to cleave in the Aβ domain and further 
N-terminal in the APP ectodomain at multiple sites, result-
ing in higher APPs levels in brain tissue of meprin β−/− KO 
mice [33, 66]. Taken together, these studies provide further 
evidence that the mechanisms controlling APPs levels in the 
brain are more complex than previously thought and involve 
multiple proteases and cell types.
In the SDS-soluble brain fractions of 12-month-old 
5xFAD mice, we observed a 50% reduction in Aβ4–40 and 
unchanged Aβ1–x levels in the ADAMTS4 KO background. 
While these results conﬁrmed our tissue culture ﬁndings and 
proved the relevance of ADAMTS4 for Aβ4–x peptide gen-
eration in vivo, they further indicated that other proteases 
might participate in the production of these N-truncated Aβ 
species. One candidate protease could be the zinc metal-
loendopeptidase neprilysin (NEP), which is localized to 
the plasma membrane and functions to degrade extracel-
lular peptides. NEP primarily cleaves at sites that feature 
a hydrophobic or aromatic amino acid residue C-termi-
nal to the scissile bond in the P1ƍ position [26]. NEP is a 
major Aβ degrading enzyme, and until now has been the 
only protease demonstrated to cleave the  Glu3–Phe4 bond 
in vitro [28]. However, in vivo studies have indicated that 
the rate-limiting step in the degradation of Aβ by neprilysin 
is cleavage of the  Gly9–Tyr10 bond, which would prevent 
the formation of full-length Aβ4–40 and Aβ4–42 peptides 
[30]. Alternatively, other ADAMTS proteases with similar 
substrate speciﬁcity to ADAMTS4 might also contribute to 
Aβ4–x peptide generation, but little is known about their 
protein expression levels and functions in the brain [22]. 
The Aβ ELISA measurements further revealed that Aβ4–40 
peptides have low abundance in the brain of 5xFAD mice 
compared to full-length Aβ1–x peptides. In 5-month-old 
5xFAD mice, we previously reported Aβ4–40 levels to 
be approximately 75-fold and 200-fold lower compared 
to Aβ1–40 and Aβ1–42 levels [79]. In the 12-month-old 
5xFAD animals in this study, the ratio of Aβ1–40/Aβ4–40 
peptides remained similar while the Aβ1–42/Aβ4–40 ratio 
increased to around 1500-fold, likely due to the substan-
tial progress of the amyloid pathology in the 5xFAD model 
between 5 and 12 months of age. A similar predominance of 
Aβ1–x over N-truncated Aβ peptides has been observed in 
other APP-transgenic mouse models [36, 41]. The low abun-
dance of Aβ4–x peptides in the 5xFAD model does provide 
a straightforward explanation for the observation that the 
overall amyloid plaque load was not aﬀected at 12-months 
of age in the ADAMTS4 KO background. In addition, the 
low Aβ4–x peptide levels in 5xFAD mice point to major 
diﬀerences in the composition of amyloid deposits between 
common AD mouse models and the human disease as stud-
ies have supported a high prevalence of Aβ4–x peptides in 
human AD brains [45, 48, 50, 51, 58, 59, 68]. Why Aβ4–x 
peptides accumulate to a much lower extent in 5xFAD mice 
as compared to human AD brain tissue is unclear at this 
point. Species speciﬁc diﬀerences in the brain biochemistry 
and the much shorter life span of mice might account for the 
diﬀerences, but the reasons might also at least in part relate 
to the design of APP-transgenic mouse models. In 5xFAD as 
in other AD mouse models the APP transgene is driven by 
promotors that direct expression mainly to neurons. There-
fore, the co-expression of ADAMTS4 and the APP substrate 
in oligodendrocytes might be insuﬃcient to generate more 
substantial amounts of Aβ4–x peptides. However, further 
studies are evidently required to fully understand the low 
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abundance of Aβ4–x and other N-truncated Aβ peptides in 
AD animal models [36, 41].
Neurons are thought to be the main source of Aβ peptides 
in the brain, but glial cells also produce Aβ [55]. Pertinent 
to our study, oligodendrocytes have been suggested to pro-
duce Aβ peptides in similar amounts to neurons [70]. Previ-
ous studies had detected ADAMTS4 protein expression by 
immunohistochemistry in the human, mouse and rat CNS 
in neurons, astrocytes and oligodendrocytes, but none of 
these studies had included ADAMTS4 KO tissue sections as 
genetic controls to validate the speciﬁcity of the employed 
commercial antibodies [19, 23, 39, 43]. Surprisingly, our 
studies using β-galactosidase reporter mice demonstrated 
that ADAMTS4 was exclusively expressed by oligodendro-
cytes in the adult murine brain. However, several previous 
studies had also strongly suggested that ADAMTS4 could be 
an oligodendrocyte-speciﬁc gene. First, an in situ hybridiza-
tion study had detected ADAMTS4 mRNA speciﬁcally in 
oligodendrocytes of the mouse hippocampus and cortex at 
P21, and in co-localization studies the riboprobe only bound 
to cells positive for the oligodendrocyte marker Olig2 [44]. 
Second, a state-of-the-art transcriptome study of all major 
brain cell types had indicated that ADAMTS4 is speciﬁ-
cally expressed in oligodendrocytes [82]. In his study, brain 
cell populations were acutely isolated from postnatal mice 
with a combination of immunopanning and ﬂuorescence-
activated cell sorting and analyzed by RNA-sequencing. In 
the resulting cell type-speciﬁc transcriptomes, ADAMTS4 
was highly expressed in myelinating and mature oligoden-
drocytes but not in neurons, astrocytes, microglia, endothe-
lial cells or pericytes [82]. This was further confirmed 
in a proteome study of murine brain cell types, in which 
ADAMTS4 belonged to the 10 most abundant proteins 
speciﬁcally expressed in cultured murine oligodendrocytes 
[69]. Most importantly, during the preparation of this manu-
script, another research group had reported the use of the 
same  ADAMTS4−/− KO reporter mouse strain to study the 
expression of ADAMTS4 in the brain, and had also detected 
ADAMTS4 in oligodendrocytes [61]. In the adult mouse 
brain, expression of β-galactosidase was exclusively local-
ized to Olig2-positive oligodendrocytes. Further studies 
demonstrated that ADAMTS4 expression was restricted to 
cells co-expressing adenomatous-polyposis-coli protein, 
a marker for mature oligodendrocytes [61]. Finally, the 
exclusive expression of ADAMTS4 in oligodendrocytes 
is consistent with our immunohistochemical detection of 
Aβ4–x peptides in white matter ﬁber tracts and neuronal 
processes in cortical areas. This novel pool of Aβ4–x pep-
tides was dependent on the expression of ADAMTS4, in 
contrast to the previously reported Aβ4–x peptides in amy-
loid plaque cores [11, 79], which appeared unchanged in 
the  ADAMTS4−/− KO background. Aβ4–x peptides have 
displayed aggregation properties and toxicity comparable 
to Aβ1–42 peptides, which are regarded as a key trigger in 
the pathogenesis of AD [7, 11, 14, 56]. Consequently, the 
presence of Aβ4–x peptides in white matter structures might 
contribute to demyelination and white matter damage. Neu-
ropathological, biochemical, and imaging studies have all 
provided evidence for white matter abnormalities and oligo-
dendrocyte dysfunction in the brains of AD patients [10, 13, 
52, 65]. Most intriguingly, magnetic resonance and diﬀusion 
tensor imaging have documented white matter abnormalities 
already in pre-symptomatic carriers of early-onset familial 
AD mutations [42, 64]. However, whether mouse models 
of AD display white matter abnormalities has been contro-
versial and contradictory ﬁndings have been reported for 
commonly used mouse lines [17, 25, 37, 72], in line with the 
fact that these models mainly replicate the amyloidosis but 
not the degenerative hallmarks of AD [34]. The etiology of 
white matter lesions in AD is unknown and it has been pro-
posed that oligodendrocyte degeneration occurs mainly sec-
ondary to the loss of neurons and axons (so called Wallerian 
degeneration) [49]. On the other hand, studies have shown 
that Aβ peptides are cytotoxic to oligodendrocytes and that 
they accumulate in white matter structures [12, 16, 32, 65, 
80], raising the possibility that N-truncated Aβ4–x peptides 
produced by oligodendrocytes or in myelinated axons could 
be uniquely harmful. This putative pathogenic mechanism 
should be investigated further, which will likely require new 
animal models that account for a pro-amyloidogenic role of 
oligodendrocytes in the pathogenesis of AD.
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